Immunological Reactivity of Blood from Healthy Humans to the rAls3p‐N Vaccine Protein
Authors:
- 1 February 2010
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 201 (3) , 473-477
Abstract
We determined reactivity of human blood to a vaccine based on the recombinant N-terminus of candidal Als3p (rAls3p-N) in preparation for future clinical trials. Healthy donor plasma had high immunoglobulin G titers (median, 1:51,200) and lower immunoglobulin A (median, 1:3,200) and immunoglobulin E (median, 1:128) titers to rAls3p-N by enzyme-linked immunosorbent assay. rAls3p-N stimulated interferon gamma (IFN-gamma) and interleukin (IL)-17, but not IL-4, from donor lymphocytes by enzyme-linked immunosorbent spot assay and IL-12 p70, IFN-gamma, IL-17, and IL-10 by cytometric bead array. Donors reacted to diverse immunodominant epitopes. Thus, facile humoral and cellular assays can monitor immune responses to the rAls3p-N vaccine in planned clinical trials.Keywords
This publication has 15 references indexed in Scilit:
- The Antifungal Vaccine Derived from the Recombinant N Terminus of Als3p Protects Mice against the BacteriumStaphylococcus aureusInfection and Immunity, 2008
- Vaccines: Correlates of Vaccine‐Induced ImmunityClinical Infectious Diseases, 2008
- Antibody Titer Threshold Predicts Anti‐Candidal Vaccine Efficacy Even though the Mechanism of Protection Is Induction of Cell‐Mediated ImmunityThe Journal of Infectious Diseases, 2008
- Considerable Differences in Vaccine Immunogenicities and Efficacies Related to the Diluent Used for Aluminum Hydroxide AdjuvantClinical and Vaccine Immunology, 2008
- Nosocomial fungal infections: epidemiology, diagnosis, and treatmentMedical Mycology, 2007
- Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance StudyClinical Infectious Diseases, 2004
- Candida albicans ALS3 and insights into the nature of the ALS gene familyCurrent Genetics, 1998
- Responses of children immunized with capsular polysaccharide of Hemophilus influenzae type b, by David H. Smith, MD, et al, Pediatrics, 1973;52:637-644; and Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100 000 vaccinees 3 months to 5 years of age in Finland, by Heikki Peltola, MD et al, Pediatrics, 1977;60:730-737.1998
- Antibody to Capsular Polysaccharides of Streptococcus pneumoniae: Prevalence, Persistence, and Response to RevaccinationClinical Infectious Diseases, 1993
- Epidemiological Studies of Streptococcus pneumoniae in Infants: Antibody to Types 3, 6, 14, and 23 in the First Two Years of LifeThe Journal of Infectious Diseases, 1988